otonomy - Otonomy shuts shop lays off employees eaug after string of failures Otonomy fails phase 3 adding another twist to ear disease saga Feb 22 2022 Otonomy develops innovative drugs for hearing loss and tinnitus using a novel delivery technology to the ear It is currently conducting a Phase 2 trial of OTO313 a NMDA receptor antagonist for tinnitus and expects topline results in mid2022 Feb 22 2021 Otonomy now has treatments for tinnitus and hearing loss in clinical development and several assets in preclinical including a gene therapy treatment for congenital hearing loss With 86 million Otonomy Announces Plan to Liquidate Company Following Number After Disappointing Phase 2 Trial in Tinnitus Otonomy to Otonomy Reports Positive TopLine Results from Phase 2a Otonomy eyes clinical trial of hearing loss gene therapy with Otonomy Reports Results from Clinical Evaluation of OTO413 Otonomy Reports Results from Phase 2 Clinical Trial of OTO Aug 1 2022 Otonomy a biopharmaceutical company developing products for neurotology announced that OTO313 a drug for tinnitus did not show any benefit over placebo in a randomized trial The company will focus on OTO413 a drug for hearing loss which showed positive results in Phase 2a Dec 20 2022 Otonomy Incs NASDAQ OTIC board of directors has approved and adopted a Plan of Liquidation and Dissolution that would include the distribution of remaining cash to stockholders following an Dec 20 2022 Otonomy a biopharmaceutical company developing ear drugs announced a plan to dissolve and distribute remaining cash to stockholders The decision follows the failure of several clinical trials and a reduction in workforce Otonomy Company Profile Office Locations Competitors May 14 2021 Otonomy and Applied Genetic Technologies Corporation are preparing to start a clinical trial of OTO825 a gene therapy that restores the function and structure of the inner ear in mice with GJB2 mutations The drug uses an adenoassociated virus vector to deliver the CX26 protein which forms gap junctions in nonsensory cells of the cochlea Jul 18 2024 Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration May 14 2021 Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration Otonomy Adopts Dissolution Liquidation Plans Implements Otonomy Crunchbase Company Profile Funding Apr 19 2021 SAN DIEGO April 19 2021 GLOBE NEWSWIRE Otonomy Inc Nasdaq OTIC a biopharmaceutical company dedicated to the development scph5501.bin of innovative therapeutics for neurotology today announced the Hearing loss biotech Otonomy plans to dissolve BioPharma Dive Otonomy Provides Corporate Update Yahoo Finance Dec 20 2022 Otonomy announced it will liquidate its assets and shut down after two clinical trial failures in recent months The company had been working on treatments for hearing loss and tinnitus for nearly a decade Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Dec 19 2022 Otonomy Inc SAN DIEGO Dec 19 2022 GLOBE NEWSWIRE Otonomy Inc Nasdaq OTIC today announced that the companys board of directors after considering strategic options has approved Dec 20 2022 Otonomy a biotech that developed drugs for ear disorders has wound down operations and laid off all employees The company failed to advance any of its latestage candidates including OTO413 for hearing loss and OTO313 for tinnitus in 2022 Otonomy Announces Closing of Public Offering and Full Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery This approach has already been widely adopted for the delivery of shortacting antibiotics to treat otitis media through a tympanostomy tube Feb 22 2021 Otonomy develops innovative drugs for ear diseases such as Ménières disease hearing loss and tinnitus The company announced the failure of its Phase 3 trial of OTIVIDEX for Ménières disease in February 2021 Mar 29 2023 SAN DIEGO CALIFORNIA Spiral Therapeutics a clinicalstage company specializing in therapies for inner ear disorders has successfully completed the acquisition of selected assets from Otonomy This followed the stockholder approval of Otonomys dissolution The acquisition includes preclinical and clinical data related to OTO104 OTIVIDEX OTO510 an otoprotectant and preclinical Apr 20 2022 Otonomy a biopharmaceutical company announced positive results from a clinical trial of OTO413 a neurotrophic factor for hearing loss patients OTO413 improved speechinnoise hearing tests and patient perception of change versus placebo at two time points Otonomy Completes Enrollment in Phase 2 Clinical Trial of SAN DIEGO Aug 01 2022 GLOBE NEWSWIRE Otonomy Inc NASDAQ OTIC a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology today announced that Mar 29 2023 Spiral Therapeutics a company focused on hearing loss and balance disorders acquires data patent rights and inventory from Otonomy a biotech company Spirals lead candidate SPT2101 shows superiority to Otonomys OTO104 in a Phase 2 trial for Ménières disease Otonomy Presents Encouraging Preclinical Data for OTO825 Otonomy Announces TopLine Results for the Phase 3 Clinical Otonomy intends to explore strategic options to advance and realize value from its pipeline including both OTO413 and OTO825 SAN DIEGO Oct 13 2022 GLOBE NEWSWIRE Otonomy Inc Nasdaq Spiral Therapeutics Acquires Otonomy sukrin Assets to Enhance Inner
mxxxiv
seloka
